HIMSS: Axolotl debuts Elysium Open Access platform

Axolotl unveiled its Elysium Open Access web services-based platform at the HIMSS10 show in Atlanta last week. In addition, the company demonstrated its integration capabilities with a variety of other vendors’ systems at the HIMSS10 Interoperability Showcase.

Elysium Open Access’ service-oriented architecture (SOA) enables critical applications to connect to an HIE via exposed web services, bringing speed to value while simplifying implementation and reducing associated costs, said Anand Shroff, Axolotl’s vice president of engineering.

Elysium Open Access is “a productized version of our services, now completely wired into our entire product portfolio,” Shroff said. “Anybody who uses our HIE platform can use Open Elysium to integrate with other applications or systems.”

Elysium Open Access enables data sharing with external systems such as personal health records (PHRs), immunization registries, public health organizations and other HIEs through purpose-specific data gateways, according to the San Jose, Calif.-based company.

Elysium Open Access uses industry standards such as HL7, IHE and CCD/CCR to support both browser-based and mobile applications. Third-party partner applications integrated through Elysium Open Access will work seamlessly with Axolotl’s software-as-a-service products, which include a communitywide Master Patient Index, Interoperability Hub, Community Virtual Health Record, and certified ambulatory EMR with integrated e-prescribing and CPOE, the company said.

 

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.